Last reviewed · How we verify
V0034CR01B
This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL).
At a glance
| Generic name | V0034CR01B |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BTK is a key component in the B-cell receptor signaling pathway, and its inhibition has been shown to be effective in treating certain types of non-Hodgkin lymphoma. By blocking BTK, this drug reduces the proliferation and survival of malignant B cells.
Approved indications
- Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
- Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Diarrhea
Key clinical trials
- Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis (PHASE3)
- Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V0034CR01B CI brief — competitive landscape report
- V0034CR01B updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI